Danazol for Treatment of Cytopenias in Patients With Cirrhosis
Status:
Not yet recruiting
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
This is a phase II pilot study designed to assess the safety and efficacy of danazol for
treatment of cytopenias in patients with CPC A/B cirrhosis. Subjects with or without telomere
mutations and/or shortened telomeres will be treated with danazol 600 mg per day by mouth for
a duration of 24 months. The goal will be to treat a total of 10 patients.